Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > BUSINESS
BUSINESS
- BMKK, Ono Initiate Multinational PIIIb Study of Orencia in Japan
December 21, 2015
- Ohara Files Japan NDA for ALL Drug Crisantaspase
December 18, 2015
- Taiho, Meiji Seika Pharma to Comarket Allergy Drug
December 18, 2015
- AbbVie Files Viekirax for Genotype 2 Hepatitis C
December 18, 2015
- Opdivo Gets Lung Cancer Indication in Japan: Ono
December 18, 2015
- Takeda to Divest Respiratory Biz to AstraZeneca
December 17, 2015
- Ex-Novartis Employee Pleads Not Guilty over Diovan Data Manipulation
December 17, 2015
- Takeda, Kyoto University Kick Off iPS Projects Targeting 6 Diseases
December 16, 2015
- LEO Pharma “Eager to Do More” after Astellas Deal to Expand Globally: CEO
December 16, 2015
- JPO Says Patents for Alimta Vitamin Therapy Valid until 2021
December 16, 2015
- Mitsubishi Tanabe Gains Exclusive Rights to Akebia’s Anemia Drug in Asia
December 16, 2015
- Mundipharma Poised to Expand Japan Operations by Tapping Isodine Brand: Asia Head
December 15, 2015
- Daiichi Sankyo Looking for a Partner to Codevelop GPR119 Agonist: CEO Nakayama
December 15, 2015
- GSK to Supply Tenozet by Imports from Gilead
December 15, 2015
- Astellas Joins Hands with US Biopharma Bellicum on Cancer Cell Therapy
December 14, 2015
- Novartis Submits Business Improvement Plan over ADR Reporting Delays
December 14, 2015
- ASKA to Launch Authorized Generics of Unisia in March
December 14, 2015
- Ono Files Opdivo for Kidney Cancer, Third Indication in Japan
December 14, 2015
- Mundipharma to Link Up with Shionogi on Isodine Brand, Dissolve Ties with Meiji Seika Pharma
December 11, 2015
- M&As among Generic Makers Would Reap No Benefits: Sawai President
December 11, 2015
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…